非酒精性脂肪性肝病与心力衰竭风险:JACC 本周综述
该综述概述了非酒精性脂肪性肝病(NAFLD)与新发心力衰竭(HF)风险之间的关联,指出两者存在强且独立的关联,并涉及多种潜在病理生理机制;风险大小与 NAFLD 严重程度(尤其肝纤维化水平)平行。NAFLD 患者可出现加速的冠状动脉粥样硬化、心肌改变(主要为心脏重构和肥厚)及某些心律失常(主要为房颤),这些可能先于并促进新发 HF。
要点
- NAFLD 与新发 HF 风险存在强且独立的关联
- 风险大小与 NAFLD 严重程度平行,尤其肝纤维化水平
- NAFLD 可加速冠脉粥样硬化、心肌重构肥厚及房颤,促进 HF 发生
核心结论
- NAFLD 与新发心力衰竭风险存在强且独立的关联,且风险大小与 NAFLD 严重程度(尤其肝纤维化水平)平行。
研究设计与样本
- 本文为简要叙述性综述(JACC Review Topic of the Week),旨在概述 NAFLD 与新发 HF 风险增加的关联、相关机制及可能降低 HF 风险的 NAFLD 靶向药物治疗。
主要发现
- NAFLD 患者可出现加速的冠状动脉粥样硬化、心肌改变(主要为心脏重构和肥厚)及某些心律失常(主要为房颤),这些可能先于并促进新发 HF 的发生。
临床怎么用
- 综述提出针对 NAFLD 的靶向药物治疗可能同时降低 HF 风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems. Emerging evidence supports a strong and independent association between NAFLD and the risk of new-onset HF, and there are multiple potential pathophysiological mechanisms by which NAFLD may increase risk of new-onset HF. The magnitude of this risk parallels the underlying severity of NAFLD, especially the level of liver fibrosis. Patients with NAFLD develop accelerated coronary atherosclerosis, myocardial alterations (mainly cardiac remodeling and hypertrophy), and certain arrhythmias (mainly atrial fibrillation), which may precede and promote the development of new-onset HF. This brief narrative review aims to provide an overview of the association between NAFLD and increased risk of new-onset HF, discuss the underlying mechanisms that link these 2 diseases, and summarize targeted pharmacological treatments for NAFLD that might also reduce the risk of HF.
引用
- Mantovani, Byrne, Benfari, et al. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022. PMID: 35027111. doi:10.1016/j.jacc.2021.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。